Two-year efficacy and safety of anti-interleukin-5/receptor therapy for eosinophilic granulomatosis with polyangiitis

Journal:
Annals of the Rheumatic Diseases
Published:
DOI:
10.1016/j.ard.2025.06.2131
Affiliations:
22
Authors:
20
Institutions Authors Share
AstraZeneca Gaithersburg, MD, United States of America (USA)
3.000000
0.15
AstraZeneca Cambridge, United Kingdom (UK)
2.000000
0.10
AstraZeneca Sweden, Sweden
2.000000
0.10
AstraZeneca, United Kingdom (UK)
1.000000
0.05
Erasme Hospital, Belgium
1.000000
0.05
University of Pennsylvania (Penn), United States of America (USA)
1.000000
0.05
University of Cambridge, United Kingdom (UK)
1.000000
0.05
Hôpital Arnaud de Villeneuve, CHU de Montpellier, France
1.000000
0.05
Mayo Clinic, United States of America (USA)
1.000000
0.05
St. Joseph's Healthcare Hamilton (SJHH), HHS, Canada
1.000000
0.05
McMaster University, Canada
1.000000
0.05
National Jewish Health (NJH), United States of America (USA)
1.000000
0.05
Mount Sinai Hospital (MSH), U of T, Canada
0.500000
0.03
University Health Network (UHN), U of T, Canada
0.500000
0.03
Guy's and St Thomas' NHS Foundation Trust, United Kingdom (UK)
0.500000
0.03
Medius KLINIKEN gemeinnutzige GmbH, Germany
0.500000
0.03
University of Tübingen (Uni Tübingen), Germany
0.500000
0.03
King's College London (KCL), United Kingdom (UK)
0.500000
0.03
Cochin Hospital, France
0.500000
0.03
Paris Cité University, France
0.500000
0.03